# Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)

> **NCT00508664** · PHASE2 · COMPLETED · sponsor: **ClinAssess** · enrollment: 180 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Hypopharynx
- Larynx Carcinoma

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Cetuximab
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin (TP)
- **DRUG:** 5-Fluorouracil (TPF) (only until Feb 2009)

## Key facts

- **NCT ID:** NCT00508664
- **Lead sponsor:** ClinAssess
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2015-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508664, "Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00508664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*